Metronomic therapy can increase quality of life during paediatric palliative cancer care, but careful patient selection is essential

被引:10
作者
Porkholm, Mikaela [1 ,2 ]
Toiviainen-Salo, Sanna [2 ,3 ]
Seuri, Raija [2 ,3 ]
Lonnqvist, Tuula [2 ,4 ]
Vepsalainen, Kaisa [5 ]
Saarinen-Pihkala, Ulla M. [1 ,2 ]
Pentikainen, Virve [1 ,2 ]
Kivivuori, Sanna-Maria [1 ,2 ]
机构
[1] Univ Helsinki, Childrens Hosp, Div Hematol Oncol & Stem Cell Transplantat, Helsinki, Finland
[2] Helsinki Univ Hosp, Helsinki, Finland
[3] Univ Helsinki, Helsinki Med Imaging Ctr, Dept Pediat Radiol, Helsinki, Finland
[4] Univ Helsinki, Div Child Neurol, Helsinki, Finland
[5] Kuopio Univ Hosp, Dept Pediat, Kuopio, Finland
关键词
Celecoxib; Etoposide; Metronomics; Paediatric; Thalidomide; ANTI-ANGIOGENIC THERAPY; PHASE-II; PROGRESSIVE CANCER; DOSE CHEMOTHERAPY; ORAL TOPOTECAN; SOLID TUMORS; CHILDREN; RECURRENT; REGIMEN; THALIDOMIDE;
D O I
10.1111/apa.13338
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Aim: Children with refractory or high-risk malignancies frequently suffer from poor quality of life during palliative care. This study explored the effect of metronomic drug administration on survival and quality of life in paediatric patients with various refractory or high-risk tumours. Methods: We treated 17 patients with a maintenance therapy that consisted of metronomic thalidomide, etoposide and celecoxib. The endpoints of the study were overall and progression-free survival, changes in the Karnofsky-Lansky scores from baseline to the end of the study therapy and radiological responses. Results: The median overall survival after the start of the study therapy was 6.2 months (range 2.0-57.7), and the six-, 12- and 24-month survival rates were 59%, 18% and 18%, respectively. The median progression-free survival was 3.2 months (range 0.3-17.8). The Karnofsky-Lansky scores increased significantly during the study therapy (p = 0.02), with 35% of the patients having a transient improvement in their clinical status. Radiologically, one partial response and two disease stabilisations were encountered. Grade III-V adverse events occurred in 76% of the patients. Conclusion: Metronomic therapy may increase the quality of life during palliative care for childhood cancer, but requires careful patient selection to minimise the risk of serious adverse events.
引用
收藏
页码:946 / 951
页数:6
相关论文
共 26 条
[1]   Metronomic etoposide/cyclophospliamide/celecoxib regimen given to children and adolescents with refractory cancer: A preliminary monocentric study [J].
Andre, Nicolas ;
Rome, Angelique ;
Coze, Carole ;
Paclovani, Laetitia ;
Pasquier, Eddy ;
Camoin, Laurence ;
Gentet, Jean Claude .
CLINICAL THERAPEUTICS, 2008, 30 (07) :1336-1340
[2]   Metronomics: towards personalized chemotherapy? [J].
Andre, Nicolas ;
Carre, Manon ;
Pasquier, Eddy .
NATURE REVIEWS CLINICAL ONCOLOGY, 2014, 11 (07) :413-431
[3]  
André N, 2011, ONCOTARGET, V2, P960
[4]  
Bello L, 2001, CANCER RES, V61, P7501
[5]   Development of a Quality of Life Instrument for Children With Advanced Cancer: the Pediatric Advanced Care Quality of Life Scale (PAC-QoL) [J].
Cataudella, Danielle ;
Morley, Tara Elise ;
Nesin, April ;
Fernandez, Conrad V. ;
Johnston, Donna Lynn ;
Sung, Lillian ;
Zelcer, Shayna .
PEDIATRIC BLOOD & CANCER, 2014, 61 (10) :1840-1845
[6]   Feasibility of metronomic maintenance chemotherapy following high-dose chemotherapy for malignant central nervous system tumors [J].
Choi, L. Mi Rim ;
Rood, Brian ;
Kamani, Naynesh ;
La Fond, Deborah ;
Packer, Roger J. ;
Santi, Maria Rita ;
MacDonald, Tobey J. .
PEDIATRIC BLOOD & CANCER, 2008, 50 (05) :970-975
[7]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247
[8]   Children Treated With Metronomic Chemotherapy in a Low-income Country: METRO-MALI-01 [J].
Fousseyni, Traore ;
Diawara, Maimouna ;
Pasquier, Eddy ;
Andre, Nicolas .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2011, 33 (01) :31-34
[9]   Thalidomide [J].
Franks, ME ;
Macpherson, GR ;
Figg, WD .
LANCET, 2004, 363 (9423) :1802-1811
[10]   Metronomic chemotherapy: An attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance [J].
Kareva, Irina ;
Waxman, David J. ;
Klement, Giannoula Lakka .
CANCER LETTERS, 2015, 358 (02) :100-106